62
Participants
Start Date
April 30, 2008
Primary Completion Date
February 29, 2012
Study Completion Date
December 31, 2012
MLN4924
IV dose escalation for 5 consecutive days followed by a rest period of 16 days for a 21 day cycle. Treated may continue until disease progression or unacceptable toxicity develops.
Emory University Hospital, Atlanta
Cancer Therapy & Research Center at the UT Health Science Center, San Antonio
Institute for Drug Development, San Antonio
Lead Sponsor
Millennium Pharmaceuticals, Inc.
INDUSTRY